Tiffany A. Traina
A5019041034- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Metabolism, Diabetes, and Cancer
- Prostate Cancer Treatment and Research
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- BRCA gene mutations in cancer
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- DNA Repair Mechanisms
- Cancer, Lipids, and Metabolism
- Cancer-related cognitive impairment studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Breast Lesions and Carcinomas
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
Memorial Sloan Kettering Cancer Center
2016-2025
Alliance Foundation Trials
2025
Kettering University
2009-2024
Cornell University
2011-2023
City Of Hope National Medical Center
2014-2022
City of Hope
2014-2022
Beckman Research Institute
2022
Hospital General Universitario de Alicante Doctor Balmis
2022
Faculty of 1000 (United States)
2020
Weill Cornell Medicine
2018-2019
With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for support tool that distills the implications associated with specific mutation events into standardized and easily interpretable format. To this end, we developed OncoKB, expert-guided precision oncology knowledge base.
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which expressed in majority cancers, coupled to SN-38 (topoisomerase I inhibitor) through proprietary hydrolyzable linker.
Patients with hormone receptor-negative breast cancer generally do not benefit from endocrine-targeted therapies. However, a subset androgen receptor (AR) expression is predicted to respond antiandrogen This phase II study explored bicalutamide in AR-positive, estrogen (ER), and progesterone (PgR)-negative metastatic cancer.Tumors patients ER/PgR-negative advanced were tested centrally for AR [immunohistochemistry (IHC) > 10% nuclear staining considered positive]. If either the primary or...
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated antitumor activity safety enzalutamide in locally advanced or metastatic AR-positive TNBC. Patients Methods Tumors were tested for immunohistochemistry assay optimized cancer; nuclear staining > 0% was considered positive. received 160 mg once per day until disease progression. The...
The identification of patients with metastatic triple-negative breast cancer (mTNBC) who are expected to benefit from platinum-based chemotherapy is interest. We conducted a single-arm phase II clinical trial single-agent platinum for mTNBC biomarker correlates.Patients received first- or second-line cisplatin (75 mg/m(2)) carboplatin (area under the concentration-time curve 6) by physician's choice once every 3 weeks. Coprimary end points were objective response rate (RR) and prediction...
Abstract Purpose: In breast cancer, somatic mutations in the PIK3CA gene are common. The prognostic implication of these activating remains uncertain as moderately sized studies have yielded variable outcomes. Our aim was to determine implications cancer. Experimental Design: Archival formalin-fixed paraffin-embedded primary tumors, from 590 patients selected for known vital status with a median follow-up 12.8 years and tumor >1 cm, were genotyped mutations. Mutation rates...
To examine the androgen receptor (AR) levels in breast cancer and to assess impact of AR expression on patient outcomes.Reverse-phase protein arrays were used measure a mass spectroscopy-based approach was detect PIK3CA mutations. Means SDs generated for levels. Linear regression models determine if differed by tumor subtype mutation status. Two-sample t tests identify pair-wise differences. Survival probabilities estimated with use Kaplan-Meier product log-rank test.The median age 59 years...
To determine if older patients with breast cancer have cognitive impairment before systemic therapy.Participants were newly diagnosed nonmetastatic and matched friend or community controls age > 60 years without prior treatment, dementia, neurologic disease. Participants completed surveys a 55-minute battery of 17 neuropsychological tests. Biospecimens obtained for APOE genotyping, clinical data abstracted. Neuropsychological test scores standardized using control means standard deviations...
1003 Background: The AR may be a therapeutic target for pts with androgen-driven TNBC. ENZA, potent inhibitor, is approved in men metastatic castration-resistant prostate cancer (mCRPC) and improves median PFS compared to bicalutamide mCRPC (15.7 vs 5.8 mos; HR 0.44; p<0.0001). Methods: MDV3100-11 was an open-label, Simon 2-stage study evaluating single agent ENZA advanced AR+ TNBC (AR >0% by IHC; NCT01889238). Pts could prescreened AR, have non-measurable bone disease unlimited prior...
This report presents the American Society of Clinical Oncology's (ASCO's) evaluation adaptations in care delivery, research operations, and regulatory oversight made response to coronavirus pandemic recommendations for moving forward as recedes. ASCO organized its clinical around five goals ensure lessons learned from COVID-19 experience are used craft a more equitable, accessible, efficient system that protects patient safety, ensures scientific integrity, maintains data quality. The...
Abstract Aims The most appropriate timing of exercise therapy to improve cardiorespiratory fitness (CRF) among patients initiating chemotherapy is not known. effects administered during, following, or during and following were examined in with breast cancer. Methods results Using a parallel-group randomized trial design, 158 inactive women cancer (neo)adjuvant allocated receive (1:1 ratio): usual care one three regimens—concurrent (during only), sequential (after concurrent (continuous) (n =...
Despite recent treatment advances, the prognosis for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) remains poor. The antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) is composed of a humanized anti-TROP2 IgG1 monoclonal antibody linked to topoisomerase I inhibitor payload via stable, cleavable linker. phase III TROPION-Breast02 trial in previously untreated TNBC, who are not candidates PD-1/PD-L1 inhibitors evaluating efficacy and...